Multiple Sclerosis Therapeutics Market Size, Share, and Trends 2026 to 2035

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology 

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Multiple Sclerosis Therapeutics Market 

5.1. COVID-19 Landscape: Multiple Sclerosis Therapeutics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Multiple Sclerosis Therapeutics Market, By Drug Class

8.1. Multiple Sclerosis Therapeutics Market, by Drug Class

8.1.1. Immunomodulators

8.1.1.1. Market Revenue and Forecast

8.1.2. Immunosuppressants

8.1.2.1. Market Revenue and Forecast

8.1.3. Monoclonal Antibodies

8.1.3.1. Market Revenue and Forecast

8.1.4. Corticosteroids

8.1.4.1. Market Revenue and Forecast

8.1.5. Sphingosine-1-Phosphate (S1P) Receptor Modulators

8.1.5.1. Market Revenue and Forecast

Chapter 9. Global Multiple Sclerosis Therapeutics Market, By Disease Type

9.1. Multiple Sclerosis Therapeutics Market, by Disease Type

9.1.1. Relapsing-Remitting Multiple Sclerosis (RRMS)

9.1.1.1. Market Revenue and Forecast

9.1.2. Secondary Progressive Multiple Sclerosis (SPMS)

9.1.2.1. Market Revenue and Forecast

9.1.3. Primary Progressive Multiple Sclerosis (PPMS)

9.1.3.1. Market Revenue and Forecast

9.1.4. Progressive-Relapsing Multiple Sclerosis (PRMS)

9.1.4.1. Market Revenue and Forecast

Chapter 10. Global Multiple Sclerosis Therapeutics Market, By Route of Administration 

10.1. Multiple Sclerosis Therapeutics Market, by Route of Administration

10.1.1. Oral

10.1.1.1. Market Revenue and Forecast

10.1.2. Injectable

10.1.2.1. Market Revenue and Forecast

10.1.3. Intravenous (IV) Infusion

10.1.3.1. Market Revenue and Forecast

Chapter 11. Global Multiple Sclerosis Therapeutics Market, By Distribution Channel

11.1. Multiple Sclerosis Therapeutics Market, by Distribution Channel

11.1.1. Hospital Pharmacies

11.1.1.1. Market Revenue and Forecast

11.1.2. Retail Pharmacies

11.1.2.1. Market Revenue and Forecast

11.1.3. Online Pharmacies

11.1.3.1. Market Revenue and Forecast

Chapter 12. Global Multiple Sclerosis Therapeutics Market, By End-use

12.1. Multiple Sclerosis Therapeutics Market, by End-use

12.1.1. Hospitals

12.1.1.1. Market Revenue and Forecast

12.1.2. Specialty Neurology Clinics

12.1.2.1. Market Revenue and Forecast

12.1.3. Homecare Settings

12.1.3.1. Market Revenue and Forecast

12.1.4. Rehabilitation Centers

12.1.4.1. Market Revenue and Forecast

Chapter 13. Global Multiple Sclerosis Therapeutics Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Drug Class

13.1.2. Market Revenue and Forecast, by Disease Type

13.1.3. Market Revenue and Forecast, by Route of Administration

13.1.4. Market Revenue and Forecast, by Distribution Channel

13.1.5. Market Revenue and Forecast, by End-use

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Drug Class

13.1.6.2. Market Revenue and Forecast, by Disease Type

13.1.6.3. Market Revenue and Forecast, by Route of Administration

13.1.6.4. Market Revenue and Forecast, by Distribution Channel

13.1.6.5. Market Revenue and Forecast, by End-use  

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Forecast, by Drug Class

13.1.7.2. Market Revenue and Forecast, by Disease Type

13.1.7.3. Market Revenue and Forecast, by Route of Administration

13.1.7.4. Market Revenue and Forecast, by Distribution Channel

13.1.7.5. Market Revenue and Forecast, by End-use

13.2. Europe

13.2.1. Market Revenue and Forecast, by Drug Class

13.2.2. Market Revenue and Forecast, by Disease Type

13.2.3. Market Revenue and Forecast, by Route of Administration

13.2.4. Market Revenue and Forecast, by Distribution Channel  

13.2.5. Market Revenue and Forecast, by End-use  

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Drug Class

13.2.6.2. Market Revenue and Forecast, by Disease Type

13.2.6.3. Market Revenue and Forecast, by Route of Administration

13.2.7. Market Revenue and Forecast, by Distribution Channel  

13.2.8. Market Revenue and Forecast, by End-use  

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Drug Class

13.2.9.2. Market Revenue and Forecast, by Disease Type

13.2.9.3. Market Revenue and Forecast, by Route of Administration

13.2.10. Market Revenue and Forecast, by Distribution Channel

13.2.11. Market Revenue and Forecast, by End-use

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Drug Class

13.2.12.2. Market Revenue and Forecast, by Disease Type

13.2.12.3. Market Revenue and Forecast, by Route of Administration

13.2.12.4. Market Revenue and Forecast, by Distribution Channel

13.2.13. Market Revenue and Forecast, by End-use

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Drug Class

13.2.14.2. Market Revenue and Forecast, by Disease Type

13.2.14.3. Market Revenue and Forecast, by Route of Administration

13.2.14.4. Market Revenue and Forecast, by Distribution Channel

13.2.15. Market Revenue and Forecast, by End-use

13.3. APAC

13.3.1. Market Revenue and Forecast, by Drug Class

13.3.2. Market Revenue and Forecast, by Disease Type

13.3.3. Market Revenue and Forecast, by Route of Administration

13.3.4. Market Revenue and Forecast, by Distribution Channel

13.3.5. Market Revenue and Forecast, by End-use

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Drug Class

13.3.6.2. Market Revenue and Forecast, by Disease Type

13.3.6.3. Market Revenue and Forecast, by Route of Administration

13.3.6.4. Market Revenue and Forecast, by Distribution Channel

13.3.7. Market Revenue and Forecast, by End-use

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Drug Class

13.3.8.2. Market Revenue and Forecast, by Disease Type

13.3.8.3. Market Revenue and Forecast, by Route of Administration

13.3.8.4. Market Revenue and Forecast, by Distribution Channel

13.3.9. Market Revenue and Forecast, by End-use

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Drug Class

13.3.10.2. Market Revenue and Forecast, by Disease Type

13.3.10.3. Market Revenue and Forecast, by Route of Administration

13.3.10.4. Market Revenue and Forecast, by Distribution Channel

13.3.10.5. Market Revenue and Forecast, by End-use

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Drug Class

13.3.11.2. Market Revenue and Forecast, by Disease Type

13.3.11.3. Market Revenue and Forecast, by Route of Administration

13.3.11.4. Market Revenue and Forecast, by Distribution Channel

13.3.11.5. Market Revenue and Forecast, by End-use

13.4. MEA

13.4.1. Market Revenue and Forecast, by Drug Class

13.4.2. Market Revenue and Forecast, by Disease Type

13.4.3. Market Revenue and Forecast, by Route of Administration

13.4.4. Market Revenue and Forecast, by Distribution Channel

13.4.5. Market Revenue and Forecast, by End-use

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Drug Class

13.4.6.2. Market Revenue and Forecast, by Disease Type

13.4.6.3. Market Revenue and Forecast, by Route of Administration

13.4.6.4. Market Revenue and Forecast, by Distribution Channel

13.4.7. Market Revenue and Forecast, by End-use

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Drug Class

13.4.8.2. Market Revenue and Forecast, by Disease Type

13.4.8.3. Market Revenue and Forecast, by Route of Administration

13.4.8.4. Market Revenue and Forecast, by Distribution Channel

13.4.9. Market Revenue and Forecast, by End-use

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Drug Class

13.4.10.2. Market Revenue and Forecast, by Disease Type

13.4.10.3. Market Revenue and Forecast, by Route of Administration

13.4.10.4. Market Revenue and Forecast, by Distribution Channel

13.4.10.5. Market Revenue and Forecast, by End-use

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Drug Class

13.4.11.2. Market Revenue and Forecast, by Disease Type

13.4.11.3. Market Revenue and Forecast, by Route of Administration

13.4.11.4. Market Revenue and Forecast, by Distribution Channel

13.4.11.5. Market Revenue and Forecast, by End-use

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Drug Class

13.5.2. Market Revenue and Forecast, by Disease Type

13.5.3. Market Revenue and Forecast, by Route of Administration

13.5.4. Market Revenue and Forecast, by Distribution Channel

13.5.5. Market Revenue and Forecast, by End-use

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Drug Class

13.5.6.2. Market Revenue and Forecast, by Disease Type

13.5.6.3. Market Revenue and Forecast, by Route of Administration

13.5.6.4. Market Revenue and Forecast, by Distribution Channel

13.5.7. Market Revenue and Forecast, by End-use

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Drug Class

13.5.8.2. Market Revenue and Forecast, by Disease Type

13.5.8.3. Market Revenue and Forecast, by Route of Administration

13.5.8.4. Market Revenue and Forecast, by Distribution Channel

13.5.8.5. Market Revenue and Forecast, by End-use

Chapter 14. Company Profiles

14.1. Biogen Inc.

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Novartis AG

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. F. Hoffmann-La Roche Ltd.

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Sanofi S.A.

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Merck KGaA

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Bristol Myers Squibb

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Johnson & Johnson

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Teva Pharmaceutical Industries

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Pfizer Inc.

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. TG Therapeutics

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms